Scientific Opinion on the safety and efficacy of L‐tryptophan, technically pure, produced by Escherichia coli strains DSM 25084, KCCM 11132P or SARI12091203 for all animal species based on a dossier submitted by AMAC EEIG
2015; Wiley; Volume: 13; Issue: 9 Linguagem: Inglês
10.2903/j.efsa.2015.4238
ISSN1831-4732
Tópico(s)Insect and Pesticide Research
ResumoEFSA JournalVolume 13, Issue 9 4238 OpinionOpen Access Scientific Opinion on the safety and efficacy of L-tryptophan, technically pure, produced by Escherichia coli strains DSM 25084, KCCM 11132P or SARI12091203 for all animal species based on a dossier submitted by AMAC EEIG EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)Search for more papers by this author EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)Search for more papers by this author First published: 30 September 2015 https://doi.org/10.2903/j.efsa.2015.4238Citations: 6 Panel members: Gabriele Aquilina, Vasileios Bampidis, Maria de Lourdes Bastos, Georges Bories, Andrew Chesson, Pier Sandro Cocconcelli, Maria Luisa Fernandez-Cruz, Gerhard Flachowsky, Jürgen Gropp, Boris Kolar, Maryline Kouba, Secundino Lopez Puente, Marta Lopez-Alonso, Alberto Mantovani, Baltasar Mayo, Fernando Ramos, Guido Rychen, Maria Saarela, Roberto Edoardo Villa, Robert John Wallace and Pieter Wester. Correspondence: feedap@efsa.europa.eu Acknowledgement: The Panel wishes to thank the members of the Working Group on Amino Acids, including Paul Brantom, Lucio Costa, Noël Dierick, Lubomir Leng and Giovanna Martelli, and the members of the FEEDAP Working Group on Genetically Modified Microorganisms, including Pier Sandro Cocconcelli, Boet Glandorf, Lieve Herman Sirpa Kärenlampi and Christoph Tebbe, for the preparatory work on this scientific opinion. Adoption date: 10 September 2015 Published date: 30 September 2015 Question number: EFSA-Q-2011-00946 On request from: European Commission AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract The product L-tryptophan is a nutritional feed additive produced by fermentation using one of three strains of Escherichia coli. L-Tryptophan produced by E. coli SARI12091203 could not be assessed because the data submitted did not permit the identity and safety of the strain, and the purity of the additive, to be determined. The EFSA Panel on Additives and Products or Substance used in Animal Feed (FEEDAP) could not conclude on the safety of this product for target animals, for consumers, users and the environment. Strain KCCM 11132P is genetically modified, but its product gives no cause for concern on GM grounds because no recombinant DNA or live bacteria were detected. l-Tryptophan produced by E. coli KCCM 11132P or E. coli DSM 25084 is safe for non-ruminant target species when supplemented to diets in appropriate amounts, but should not be given to ruminants in an unprotected form because of the formation of skatole (3-methylindole) during ruminal fermentation. l-Tryptophan produced by E. coli KCCM 11132P or E. coli DSM 25084 contains low concentrations of 1,1′-ethylidene-bis-L-tryptophan and 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid and is safe for the consumer of animal products. The level of endotoxins present in the products of E. coli KCCM 11132P or E. coli DSM 25084 and its possible dusting potential indicate an inhalation risk for the user. In the absence of data on the potential for dermal sensitisation it is concluded that such potential may exist. No other concerns for user safety (inhalation toxicity, skin and eyes irritation) regarding the L-tryptophan produced by E. coli DSM 25084 were identified. The use of the product L-tryptophan produced by E. coli KCCM 11132P or E. coli DSM 25084 in animal nutrition does not pose a risk to the environment. The products under application are efficacious sources of the amino acid L-tryptophan for animal nutrition. References Adachi J, Asano M and Ueno Y, 2000. Tetrahydro-β-carboline-3-carboxylic acids and contaminants of L-tryptophan. Journal of Chromatography A, 881, 501– 515. Bauer AP, Dieckmann SM, Ludwig W and Schleifer KH, 2007. Rapid identification of Escherichia coli safety and laboratory strain lineages based on Multiplex-PCR. Federation of European Microbiological Societies Microbiology Letters, 269, 36– 40. Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B and Shao Y, 1997. The complete genome sequence of Escherichia coli K-12. Science, 277, 1453– 1462. Cort N, Fredriksson G, Kindahl H, Edqvist LE and Rylander R, 1990. A clinical and endocrine study on the effect of orally administered bacterial endotoxin in adult pigs and goats. Journal of Veterinary Medicine Series A, 37, 130– 137. EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2010. Scientific Opinion on the use of feed additives authorised/applied for use in feed when supplied via water. EFSA Journal 2010; 8 (12): 1956, 9 pp. doi:10.2903/j.efsa.2010.1956. EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2012a. Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. EFSA Journal 2012; 10 (6): 2740, 10 pp. doi:10.2903/j.efsa.2012.2740. EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2012b. Guidance on studies concerning the safety of use of the additive for users/workers. EFSA Journal 2012; 10 (1): 2539, 5 pp. doi:10.2903/j.efsa.2012.2539. EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2013. Scientific opinion on the safety and efficacy of L-tryptophan produced by Escherichia coli (FERM BP-11200) for all animal species based on a dossier submitted by Ajinomoto Eurolysine SAS. EFSA Journal 2013; 11 (10): 3368, 2 pp. doi:10.2903/j.efsa.2013.3368. EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2014a. Scientific Opinion on the safety and efficacy of L-tryptophan produced by Escherichia coli (FERM BP-11354) for all animal species, based on a dossier submitted by Ajinomoto Eurolysine S.A.S. EFSA Journal 2014; 12 (10): 3826, 13 pp. doi:10.2903/j.efsa.2014.3826. EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2014b. Scientific Opinion on the safety and efficacy of L-tryptophan technically pure produced by fermentation with Escherichia coli for all animal species, based on a dossier submitted by HELM AG on behalf of Global Bio-Chem Technology. EFSA Journal 2014; 12 (5): 3673, 2 pp. doi:10.2903/j.efsa.2014.3673. EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2015. Scientific Opinion on the safety and efficacy of L-tryptophan produced by Escherichia coli CGMCC 7.59 for all animal species based on a dossier submitted by HELM AG on behalf of Meihua Holdings Co. Ltd. EFSA Journal 2015; 13 (2): 4015, 17 pp. doi:10.2903/j.efsa.2015.4015. EFSA GMO Panel (Panel on Genetically Modified Organisms), 2011. Scientific Opinion on Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use. EFSA Journal 2011; 9 (6): 2193, 54 pp. doi:10.2903/j.efsa.2011.2193. EFSA NDA Panel (Panel on Dietetic Products, Nutrition and Allergies), 2011. Scientific Opinion on the substantiation of health claims related to L-tryptophan and maintenance of normal sleep (ID 596, 1671), enhancement of mood (ID 596), contribution to normal cognitive function (ID 596), and contribution to the maintenance or achievement of a normal body weight (ID 604) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011; 9 (4): 2073, 16 pp. doi:10.2903/j.efsa.2011.2073. EPA (US Environmental Protection Agency), 1997. Escherichia coli K-12 derivatives final risk assessment. Available online: http://epa.gov/biotech_rule/pubs/fra/fra004.htm. European Pharmacopoeia, 2010. Tryptophan, Monograph 01/2009:1272, 7th edition. Council of Europe (COE)—European Directorate for the Quality of Medicines, Strasbourg, France. Gao B, Wang Y and Tsan MF, 2006. The heat sensitivity of cytokine-inducing effect of lipopolysaccharide. Journal of Leukocyte Biology, 80, 359– 366. Gorbach SL, 1978. Risk assessment of recombinant DNA experimentation with Escherichia coli K12. Proceedings from a workshop at Falmouth, Massachusetts. Journal of Infectious Diseases, 137, 613– 714. Hammond AC, Carlson JR and Breeze RG, 1978. Monensin and the prevention of tryptophan-induced acute bovine pulmonary edema and emphysema. Science, 201, 153– 155. Health Council of the Netherlands, 2010. Endotoxins, 2010. Health-based recommended occupational exposure limit. Publication no 2010/04OSH. Health Council of the Netherlands, The Hague, 100 pp. Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M and Gleich GJ, 1990. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. New England Journal of Medicine, 322, 869– 873. HSE (Health and Safety Executive), 2013. Occupational Hygiene implications of processing waste at materials recycling facilities (MRFs). RR977 Research Report. HSE, London, UK, 41 pp. Kaper JB, Natro JP and Mobley HLT, 2004. Pathogenic Escherichia coli. Nature Reviews Microbiology, 2, 123– 140. Le Floc'h N and Sève B, 2007. Biological roles of tryptophan and its metabolism: potential implications for pig feeding. Livestock Science, 112, 23– 32. Luchi M and Morrison DC, 2000. Comparable endotoxic properties of lipopolysaccharides are manifest in diverse clinical isolates of gram-negative bacteria. Infection and Immunity, 68, 1899– 1904. Nataro JP and Kaper JB, 1998. Diarrheagenic Escherichia coli. Clinical Microbiology Reviews, 11, 142– 201. Rylander R, 1999. Health effects among workers in sewage treatment plants. Occupational Environmental Medicine, 56, 354– 357. Svensson M, Han L, Silfersparre G, Haggstrom L and Enfors SO, 2005, Control of endotoxin release in Escherichia coli feed-batch cultures. Bioprocess and Biosystems Engineering, 27, 91– 97. Thorn J, 2001. The inflammatory response in humans after inhalation of bacterial endotoxin: a review. Inflammatory Response, 50, 254– 261. Yao K, Fang J, Yin YL, Feng ZM, Tang ZR and Wu G, 2011. Tryptophan metabolism in animals: important roles in nutrition and health. Frontiers in Bioscience (Scholar Edition), 3, 286– 297. Zamaratskaia G and Squires E, 2008. Biochemical, nutritional and genetic effects on boar taint in entire male pigs. Animal, 2, 1– 14. Citing Literature Volume13, Issue9September 20154238 ReferencesRelatedInformation
Referência(s)